Active, not recruitingNCT04860765
COMPASSION S3 Post-Approval Study
Studying Visceral heterotaxy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Edwards Lifesciences
- Intervention
- SAPIEN 3 THV(device)
- Enrollment
- 150 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2030
Study locations (19)
- University of Alabama, Birmingham, Alabama, United States
- Cedars Sinai, Los Angeles, California, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- Advocate Childrens Hospital, Oak Lawn, Illinois, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Minneapolis Heart, Minneapolis, Minnesota, United States
- St. Louis Children's Hospital, St Louis, Missouri, United States
- Newark Beth Israel Medical Center, Newark, New Jersey, United States
- Mount Sinai, New York, New York, United States
- Columbia University Medical Center/NYPH, New York, New York, United States
- Duke University, Durham, North Carolina, United States
- Cincinatti Children's Hospital, Cincinnati, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04860765 on ClinicalTrials.govOther trials for Visceral heterotaxy
Additional recruiting or active studies for the same condition.